MedTrace Logo

Effects of Glutamine on GLP-1 and Insulin Secretion in Man

NCT00673894 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2019-05-13

Study results available
· View outcomes & findings →

Summary

This study investigated the effect of glutamine, an amino acid, glycemia, glucagon-like peptide-1 (GLP-1) and insulin in participants with type 2 diabetes.

Conditions

Interventions

DRUG

Sitagliptin

Glutamine 30g +sitagliptin 100mg

DRUG

Placebo

Glutamine 30g +placebo (matching sitagliptin 100 mg)

Sponsors & Collaborators

  • Garvan Institute of Medical Research

    lead OTHER

Principal Investigators

  • Jerry R Greenfield, MD, PhD · Garvan Institute of Medical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2011-12-31
Completion
2014-11-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00673894 on ClinicalTrials.gov